Research pipeline · Not approved
CagriSemaGLP-1 agonist combined with an amylin analogue
CagriSema is an investigational combination of semaglutide, the molecule in Wegovy, with cagrilintide, an amylin analogue. In the REDEFINE 1 trial it produced a mean weight reduction of 22.7% at 68 weeks, outperforming semaglutide alone. Novo Nordisk is expected to file for approval, but it holds no marketing authorisation and cannot lawfully be prescribed or supplied.
Not available
This compound is investigational. It holds no marketing authorisation from the MHRA, EMA or FDA, so it cannot lawfully be prescribed, sold or supplied for human use in the UK or elsewhere. Products offered online as "research use only" versions of it are unlicensed medicines, of unverified identity and purity, and are outside any clinical oversight.
At a glance
- Developer
- Novo Nordisk
- Targets
- GLP-1 · Amylin
- Administration
- Once-weekly subcutaneous injection (in trials)
- Stage
- Submitted to regulators
- Reported
- 22.7% · 68 weeks
How CagriSema differs
Amylin is a separate satiety hormone released alongside insulin. Cagrilintide mimics it, adding a second and independent satiety signal to the GLP-1 mechanism.
The design is additive rather than novel: it pairs a molecule already licensed for weight management with one acting through a different pathway, which is why its efficacy sits above semaglutide alone.
Because one half of the combination is already a licensed medicine with a known profile, the regulatory question centres largely on the amylin component and the combination itself.
Clinical evidence
What the trials showed
Mean weight reduction of 22.7% at 68 weeks
CagriSema outperformed semaglutide alone over the same period, establishing the benefit of adding the amylin analogue rather than increasing GLP-1 dose.
What is known about tolerability
- Gastrointestinal effects consistent with the GLP-1 class were the most commonly reported events.
- The amylin component contributes its own tolerability profile, which the combination trials were designed to characterise.
- A full profile will be defined by regulatory review of the complete dataset, not by headline efficacy figures.
Availability
Not approved. Regulatory filing has been anticipated, but submission is not approval and review outcomes cannot be assumed. CagriSema cannot be obtained lawfully for human use in the UK.
CagriSema: Common questions
What is CagriSema?
CagriSema is an investigational once-weekly injection combining semaglutide with cagrilintide, an amylin analogue. It targets two separate satiety pathways rather than one. In the REDEFINE 1 trial it produced 22.7% mean weight reduction at 68 weeks, and it is not currently approved by any regulator.
Is CagriSema better than Wegovy?
In REDEFINE 1 it produced greater mean weight reduction than semaglutide alone, which is the molecule in Wegovy. But Wegovy is licensed and available under clinical supervision, and CagriSema is neither. An unapproved compound is not an option a prescriber can offer.
Sources
Awaiting sign-off by a named clinician.